Greenwich LifeSciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 7
- Market Cap
- $183.8M
- Introduction
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Greenwich LifeSciences, Inc.
- Target Recruit Count
- 598
- Registration Number
- NCT05232916
- Locations
- 🇺🇸
Arizona Oncology Associates - Tucson, Tucson, Arizona, United States
🇺🇸Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center, Fullerton, California, United States
🇺🇸University of California San Diego - Moores Cancer Center, La Jolla, California, United States
News
Greenwich LifeSciences Advances Phase III FLAMINGO-01 Trial for HER2-Positive Breast Cancer Immunotherapy
Greenwich LifeSciences is conducting FLAMINGO-01, a Phase III trial evaluating GLSI-100 immunotherapy to prevent breast cancer recurrences in HER2-positive patients with residual disease.
Greenwich LifeSciences Builds Internal Clinical Team to Reduce Costs and Enhance FLAMINGO-01 Breast Cancer Trial Operations
Greenwich LifeSciences is transitioning from external Clinical Research Organizations to an internal clinical trial management team for its Phase III FLAMINGO-01 study to reduce costs and improve efficiency.
Greenwich LifeSciences Reports 46% HLA-A*02 Prevalence in FLAMINGO-01 Trial for Breast Cancer Vaccine
Initial analysis of FLAMINGO-01 trial reveals 46% of screened patients carry at least one HLA-A*02 allele, a crucial factor for GLSI-100 breast cancer vaccine treatment.
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Globally, Adds New Sites and Expertise
Greenwich LifeSciences broadens its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, by adding new clinical sites in the U.S. and Europe.
MAIA Biotechnology's THIO Shows Promise in Phase II Lung Cancer Trial; Institutional Investment Increases
MAIA Biotechnology's lead candidate, THIO, is currently in Phase II clinical trials, evaluating its potential in treating patients with non-small cell lung cancer.
Greenwich LifeSciences Expands Breast Cancer Immunotherapy Trial to Italy
• Greenwich LifeSciences partners with Gruppo Italiano Mammella (GIM) to expand its Phase III FLAMINGO-01 trial in Italy. • Nine top Italian institutions will participate in evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence. • In 2022, Italy reported 58,160 new breast cancer cases, highlighting the critical need for improved treatments and preventative strategies. • Patient enrollment has commenced at Italian sites, with Professor Grazia Arpino leading as the Italian National Principal Investigator.
Greenwich LifeSciences' Flamingo-01 Trial Expands into Europe and Broadens Patient Enrollment
Greenwich LifeSciences' Flamingo-01 Phase III trial, evaluating GLSI-100 for breast cancer recurrence prevention, has been approved for expansion into Europe, including Spain, France, Germany, Italy, and Poland.